I am in BLCM. I think I have mentioned this previously. They have not had the issues that Juno has had but are still to release some data mentioned at ASCO. So they may yet be best in class. They have a safety switch which can stop the therapy if there is an adverse reaction. So they may be an obvious buy out target for Juno et al.. BLCMs price movement since the Juno problem supports both the above observations. I agree with ulingt about EXEL and CAR-T. Even given Joe's doubts which obviously may prove correct, I am planning that there will be enough hype around the therapies to unload some shares and cover the cost of the whole position if you are not completely sure.